We are live on ! Find out more
RXRX icon

Recursion Pharmaceuticals

319 hedge funds and large institutions have $2.06B invested in Recursion Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 87 funds opening new positions, 116 increasing their positions, 62 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

248% more capital inflows, than outflows

Capital inflows: $382M | Capital outflows: $110M

149% more first-time investments, than exits

New positions opened: 87 | Existing positions closed: 35

87% more repeat investments, than reductions

Existing positions increased: 116 | Existing positions reduced: 62

67% more funds holding in top 10

Funds holding in top 10: 6 → 10 (+4)

18% more funds holding

Funds holding: 270 → 319 (+49)

1% less call options, than puts

Call options by funds: $30.7M | Put options by funds: $30.9M

14.77% less ownership

Funds ownership: 94.19% → 79.42% (-15%)

Holders
319
Holders Change
+49
Holders Change %
+18.15%
% of All Funds
4.18%
Holding in Top 10
10
Holding in Top 10 Change
+4
Holding in Top 10 Change %
+66.67%
% of All Funds
0.13%
New
87
Increased
116
Reduced
62
Closed
35
Calls
$30.7​M
Puts
$30.9​M
Net Calls
-⁠$211​K
Net Calls Change
+$8.19​M

RXRX Hedge Fund Activity: Q4 2024 in Review

319 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Recursion Pharmaceuticals (RXRX) for Q4 2024, worth a combined $2.06B — up 18% from $1.74B a quarter earlier.

Buyers outnumbered sellers: 87 funds opened new RXRX positions and 35 closed out — a net gain of 52 holders — while 116 added to existing stakes and 62 trimmed.

The largest buyer was SoftBank Group, opening a new position worth an estimated $98.6M. The largest seller was RA Capital Management, cutting an estimated $51.5M.

  • 319 institutional investors held Recursion Pharmaceuticals (RXRX) as of Q4 2024, up from 270 in Q3 2024.
  • Funds reported $2.06B of Recursion Pharmaceuticals stock for Q4 2024, up 18% quarter-over-quarter.
  • 87 funds opened new Recursion Pharmaceuticals positions in Q4 2024 and 35 closed out, a net change of +52 holders.
  • The largest Recursion Pharmaceuticals buyer in Q4 2024 was SoftBank Group, an estimated $98.6M added.
  • The largest Recursion Pharmaceuticals seller in Q4 2024 was RA Capital Management, an estimated $51.5M sold.

Based on aggregated 13F filings for Q4 2024.